This Month’s Issue

The BioProcess International May 2016 downstream theme issue cover is illustrated by a downstream process suite at Rentschler Biotechnologie GmbH in Laupheim, Germany. (www.rentschler.de)

Read it Now.

CONTRACT SERVICES
Outsourcing Trends and Technical Considerations

This Contract Services supplement showcases how contract services are expanding and specializing, with examples such as biosimilars, cell therapies, development services, and fill and finish.

Read it Now.

Manufacturing

ASME BPE standard-based parts from Nordson Medical NORDSON MEDICAL (WWW.SCVSERIES.COM)

Bioprocessing Standards for Single-Use Components Are Moving Forward

With the escalating use of single-use technology in bioprocessing, suppliers have had to rapidly develop disposable components such as fittings, tubing, pumps, sensors, and flexible containers for bioprocessing. Single-use technology is growing so fast that the organizations tasked with guiding its growth are having difficulty keeping up. Contributing to this problem are factors such as company needs, regulatory requirements, market pressures, and costs. That growth has posed considerable concerns for the bioprocessing industry about the presence of organic and inorganic…

WWW.PHOTOS.COM

Manufacturing

Rapid Formulation Development for Monoclonal Antibodies

Monoclonal antibodies (MAbs) are at the focal point of biologics development. Many of the best-selling drugs are therapeutic MAbs or related proteins (1–2). The combined world-wide sales from MAbs will be nearly US$125 billion by 2020 (3). About 50 MAb products treating a range of diseases have been approved in the United States or Europe. With the large number of MAbs progressing through discovery, biomanufacturers need to accelerate process development and move projects rapidly into clinical manufacturing (4–5). Formulation development,…

© INVETECH 2016 (WWW.INVETECH.COM)

Business

Automation in Cell Therapy Manufacturing

The concept of automation conjures up images of robots on assembly lines or perhaps automobiles replacing horse-drawn carriages. In both examples, automation provides an ability to work tirelessly, with reproducible high-quality outputs at increased speed. For cell therapy, automation can be used to increase the scale of cell culture operations (e.g., bioreactors replacing flasks) and allow the use of closed systems that can protect cell products from contamination with adventitious agents from the environment or operators themselves. Closed systems also…